Modulation of tissue tropism and biological activity of exosomes and other extracellular vesicles: New nanotools for cancer treatment

Pharmacological Research

Volumn 111, Issue , 2016, Pages 487-500

  Kooijmans, Sander A A ^a   Schiffelers, Raymond M ^a   Zarovni, Natasa ^b   Vago, Riccardo ^c,d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Exosomics Siena SpA   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Cancer treatment; Diagnostic nanosystems; Drug delivery; Exosomes; Extracellular vesicles; Targeted therapy

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; B RAF KINASE; CD56 ANTIGEN; CELL PROTEIN; CISPLATIN; CURCUMIN; DNA; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GRANZYME B; K RAS PROTEIN; LIPID; LIPOSOME; MESSENGER RNA; METHOTREXATE; MICRORNA 146A; NANOPARTICLE; PACLITAXEL; PERFORIN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RNA; SMALL INTERFERING RNA; TUMOR MARKER;

ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY FLUID; BRAIN CANCER; BREAST CANCER; CANCER THERAPY; CELL COMMUNICATION; CELL ENGINEERING; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DRUG DELIVERY SYSTEM; ENCAPSULATION; EXOSOME; EXTRACELLULAR SPACE; GENETIC ENGINEERING; GLIOBLASTOMA; HUMAN; ISOTOPE LABELING; LIPID BILAYER; LIVER CELL CARCINOMA; MESENCHYMAL STEM CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PARTICLE SIZE; PERMEABILITY BARRIER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURFACE PROPERTY; THERANOSTIC NANOMEDICINE; TROPISM; ANIMAL; NEOPLASM;

ANIMALS; EXTRACELLULAR VESICLES; HUMANS; NEOPLASMS; THERANOSTIC NANOMEDICINE; TROPISM;

EID: 84978394347     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.07.006     Document Type: Article

References (146)

1. [1] De Toro, J., et al. Emerging roles of exosomes in normal and pathological conditions: new insights for diagnosis and therapeutic applications. Front. Immunol., 6, 2015, 203.
2. [2] Tickner, J.A., et al. Functions and therapeutic roles of exosomes in cancer. Front. Oncol., 4, 2014, 127.
3. [3] Gyorgy, B., et al. Therapeutic applications of extracellular vesicles: clinical promise and open questions. Annu. Rev. Pharmacol. Toxicol. 55 (2015), 439–464.
4. [4] Al-Nedawi, K., et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat. Cell Biol. 10:5 (2008), 619–624.
5. [5] Valadi, H., et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9:6 (2007), 654–659.
6. [6] Guescini, M., et al. C2C12 myoblasts release micro-vesicles containing mtDNA and proteins involved in signal transduction. Exp. Cell Res. 316:12 (2010), 1977–1984.
7. [7] Balaj, L., et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat. Commun., 2, 2011, 180.
8. [8] Kahlert, C., et al. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J. Biol. Chem. 289:7 (2014), 3869–3875.
9. [9] Thakur, B.K., et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 24:6 (2014), 766–769.
10. [10] Li, Y., et al. Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv. Drug Deliv. Rev., 2012, 29–39 (1872–8294 (Electronic)).
11. [11] van der Meel, R., et al. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv. Drug Deliv. Rev. 65:10 (2013), 1284–1298.
12. [12] Gutierrez-Puente, Y., et al. Safety: pharmacokinetics, and tissue distribution of liposomal P-ethoxy antisense oligonucleotides targeted to Bcl-2. J. Pharmacol. Exp. Ther. 291:2 (1999), 865–869.
13. [13] Landen, C.N. Jr., et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65:15 (2005), 6910–6918.
14. [14] Gray, M.J., et al. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J. Natl. Cancer Inst. 100:2 (2008), 109–120.
15. [15] Zomer, A., et al. In Vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. Cell 161:5 (2015), 1046–1057.
16. [16] Pegtel, D.M., et al. Functional delivery of viral miRNAs via exosomes. Proc. Natl. Acad. Sci. U. S. A. 107:14 (2010), 6328–6333.
17. [17] Huang, X., et al. Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics, 14, 2013 p. 319.
18. [18] Bruno, S., et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J. Am. Soc. Nephrol. 20:5 (2009), 1053–1067.
19. [19] Gatti, S., et al. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol. Dial. Transplant. 26:5 (2011), 1474–1483.
20. [20] Hill, A.F., et al. ISEV position paper: extracellular vesicle RNA analysis and bioinformatics. J. Extracell Vesicles, 2, 2013.
21. [21] Sun, D., et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol. Ther. 18:9 (2010), 1606–1614.
22. [22] Yang, Y., et al. Increased anti-tumour activity by exosomes derived from doxorubicin-treated tumour cells via heat stress. Int. J. Hyperthermia 31:5 (2015), 498–506.
23. [23] Haney, M.J., et al. Exosomes as drug delivery vehicles for Parkinson's disease therapy. J. Control. Release 207 (2015), 18–30.
24. [24] Hunt, C.A., et al. Retention of cytosine arabinoside in mouse lung following intravenous administration in liposomes of different size. Drug Metab. Dispos. 7:3 (1979), 124–128.
25. [25] Schiffelers, R.M., et al. Localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue: influence of liposome characteristics. Biochim. Biophys. Acta 1421:2 (1999), 329–339.
26. [26] Wisse, E., et al. The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Ther. 15:17 (2008), 1193–1199.
27. [27] Yuan, S., Rigor, R., Pathophysiology and clinical relevance. Regulation of Endothelial Barrier Function, 2010, Morgan & Claypool Life Sciences, San Rafael (CA) Chapter 7, Available from: http://www.ncbi.nlm.nih.gov/books/NBK54125/.
28. [28] Nehoff, H., et al. Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect. Int. J. Nanomed. 9 (2014), 2539–2555.
29. [29] Hobbs, S.K., et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U. S. A. 95:8 (1998), 4607–4612.
30. [30] Colombo, M., et al. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu. Rev. Cell Dev. Biol. 30 (2014), 255–289.
31. [31] Fuhrmann, G., et al. Cell-derived vesicles for drug therapy and diagnostics: opportunities and challenges. Nano Today 10:3 (2015), 397–409.
32. [32] Nordin, J.Z., et al. Ultrafiltration with size-exclusion liquid chromatography for high yield isolation of extracellular vesicles preserving intact biophysical and functional properties. Nanomedicine 11:4 (2015), 879–883.
33. [33] Litzinger, D.C., et al. Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim. Biophys. Acta 1281:2 (1996), 139–149.
34. [34] Wiklander, O.P., et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J. Extracell Vesicles, 4, 2015, 26316.
35. [35] Imai, T., et al. Macrophage-dependent clearance of systemically administered B16BL6-derived exosomes from the blood circulation in mice. J. Extracell Vesicles, 4, 2015, 26238.
36. [36] Morishita, M., et al. Quantitative analysis of tissue distribution of the B16BL6-derived exosomes using a streptavidin-lactadherin fusion protein and iodine-125-labeled biotin derivative after intravenous injection in mice. J. Pharm. Sci. 104:2 (2015), 705–713.
37. [37] Hazan-Halevy, I., et al. Cell-specific uptake of mantle cell lymphoma-derived exosomes by malignant and non-malignant B-lymphocytes. Cancer Lett. 364:1 (2015), 59–69.
38. [38] Rana, S., et al. Toward tailored exosomes: the exosomal tetraspanin web contributes to target cell selection. Int. J. Biochem. Cell Biol. 44:9 (2012), 1574–1584.
39. [39] Zech, D., et al. Tumor-exosomes and leukocyte activation: an ambivalent crosstalk. Cell Commun. Signal., 10(1), 2012, 37.
40. [40] Lugini, L., et al. Immune surveillance properties of human NK cell-derived exosomes. J. Immunol. 189:6 (2012), 2833–2842.
41. [41] Katakowski, M., et al. Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. Cancer Lett. 335:1 (2013), 201–204.
42. [42] Munoz, J.L., et al. Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Mol. Ther. Nucleic Acids, 2, 2013 p. e126.
43. [43] Mulcahy, L.A., et al. Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles, 3, 2014 p. 24641.
44. [44] Svensson, K.J., et al. Exosome uptake depends on ERK1/2-heat shock protein 27 signaling and lipid Raft-mediated endocytosis negatively regulated by caveolin-1. J. Biol. Chem. 288:24 (2013), 17713–17724.
45. [45] Feng, D., et al. Cellular internalization of exosomes occurs through phagocytosis. Traffic 11:5 (2010), 675–687.
46. [46] Delcayre, A., et al. Exosome Display technology: applications to the development of new diagnostics and therapeutics. Blood Cells. Mol. Dis. 35:2 (2005), 158–168.
47. [47] Alvarez-Erviti, L., et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29:4 (2011), 341–345.
48. [48] Ruiss, R., et al. EBV-gp350 confers B-cell tropism to tailored exosomes and is a neo-antigen in normal and malignant B cells—a new option for the treatment of B-CLL. PLoS One, 6(10), 2011 p. e25294.
49. [49] Tian, Y., et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 35:7 (2014), 2383–2390.
50. [50] Ohno, S., et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol. Ther. 21:1 (2013), 185–191.
51. [51] Hung, M.E., Leonard, J.N., Stabilization of exosome-targeting peptides via engineered glycosylation. J. Biol. Chem. 290:13 (2015), 8166–8172.
52. [52] Lai, C.P., et al. Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. ACS Nano 8:1 (2014), 483–494.
53. [53] Kooijmans, S.A., et al. Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting. J. Extracell Vesicles, 5, 2016 p. 31053.
54. [54] Smyth, T., et al. Surface functionalization of exosomes using click chemistry. Bioconjug. Chem. 25:10 (2014), 1777–1784.
55. [55] Iden, D.L., Allen, T.M., In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim. Biophys. Acta 1513:2 (2001), 207–216.
56. [56] Moreira, J.N., et al. Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity. Pharm. Res. 19:3 (2002), 265–269.
57. [57] Uster, P.S., et al. Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time. FEBS Lett. 386:2–3 (1996), 243–246.
58. [58] Sou, K., et al. Poly(ethylene glycol)-modification of the phospholipid vesicles by using the spontaneous incorporation of poly(ethylene glycol)-lipid into the vesicles. Bioconjug. Chem. 11:3 (2000), 372–379.
59. [59] Suk, J.S., et al. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 99:Pt A (2016), 28–51.
60. [60] Nag, O.K., Awasthi, V., Surface engineering of liposomes for stealth behavior. Pharmaceutics 5:4 (2013), 542–569.
61. [61] Kooijmans, S.A., et al. Exosome mimetics: a novel class of drug delivery systems. Int. J. Nanomed. 7 (2012), 1525–1541.
62. [62] Clayton, A., Mason, M.D., Exosomes in tumour immunity. Curr. Oncol. 16:3 (2009), 46–49.
63. [63] Raposo, G., et al. B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 183:3 (1996), 1161–1172.
64. [64] Zitvogel, L., et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat. Med. 4:5 (1998), 594–600.
65. [65] Escudier, B., et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J. Transl. Med., 3(1), 2005 p. 10.
66. [66] Morse, M.A., et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J. Transl. Med., 3(1), 2005 p. 9.
67. [67] Besse, B., et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. OncoImmunology, 5(4), 2015.
68. [68] Tang, X.J., et al. Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy. Oncotarget 6:42 (2015), 44179–44190.
69. [69] Lee, C., et al. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation 126:22 (2012), 2601–2611.
70. [70] Fatima, F., Nawaz, M., Stem cell-derived exosomes: roles in stromal remodeling, tumor progression, and cancer immunotherapy. Chin. J. Cancer 34:12 (2015), 541–553.
71. [71] Bruno, S., et al. Effects of mesenchymal stromal cell-derived extracellular vesicles on tumor growth. Front. Immunol., 5, 2014 p. 382.
72. [72] Vallabhaneni, K.C., et al. Extracellular vesicles from bone marrow mesenchymal stem/stromal cells transport tumor regulatory microRNA: proteins, and metabolites. Oncotarget 6:7 (2015), 4953–4967.
73. [73] Roccaro, A.M., et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J. Clin. Invest. 123:4 (2013), 1542–1555.
74. [74] Filipazzi, P., et al. Recent advances on the role of tumor exosomes in immunosuppression and disease progression. Semin. Cancer Biol. 22:4 (2012), 342–349.
75. [75] Ju, S., et al. Grape exosome-like nanoparticles induce intestinal stem cells and protect mice from DSS-induced colitis. Mol. Ther. 21:7 (2013), 1345–1357.
76. [76] Tran, T.H., et al. Exosomes as nanocarriers for immunotherapy of cancer and inflammatory diseases. Clin. Immunol. 160:1 (2015), 46–58.
77. [77] Cooper, J.M., et al. Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov. Disord. 29:12 (2014), 1476–1485.
78. [78] Johnsen, K.B., et al. A comprehensive overview of exosomes as drug delivery vehicles—endogenous nanocarriers for targeted cancer therapy. Biochim. Biophys. Acta 1846:1 (2014), 75–87.
79. [79] Zhu, W., et al. Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo. Cancer Lett. 315:1 (2012), 28–37.
80. [80] Munagala, R., et al. Bovine milk-derived exosomes for drug delivery. Cancer Lett. 371:1 (2016), 48–61.
81. [81] Wahlgren, J., et al. Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Res., 40(17), 2012 p. e130.
82. [82] Lener, T., et al. Applying extracellular vesicles based therapeutics in clinical trials − an ISEV position paper. J. Extracell Vesicles, 4, 2015 p. 30087.
83. [83] Liu, Y., et al. Targeted exosome-mediated delivery of opioid receptor Mu siRNA for the treatment of morphine relapse. Sci. Rep., 5, 2015 p. 17543.
84. [84] Barh, D., et al. MicroRNA let-7: an emerging next-generation cancer therapeutic. Curr. Oncol. 17:1 (2010), 70–80.
85. [85] Katakowski, M., et al. MiR-146b-5p suppresses EGFR expression and reduces in vitro migration and invasion of glioma. Cancer Invest. 28:10 (2010), 1024–1030.
86. [86] Srinivasan, S., et al. A ten-microRNA expression signature predicts survival in glioblastoma. PLoS One, 6(3), 2011 p. e17438.
87. [87] O'Brien, K., et al. miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. Oncotarget 6:32 (2015), 32774–32789.
88. [88] Bao, L., et al. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am. J. Pathol. 180:6 (2012), 2490–2503.
89. [89] Pascucci, L., et al. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. J. Control. Release 192 (2014), 262–270.
90. [90] Saari, H., et al. Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells. J. Control. Release 220:Pt. B (2015), 727–737.
91. [91] Hoshino, A., et al. Tumour exosome integrins determine organotropic metastasis. Nature 527:7578 (2015), 329–335.
92. [92] Tang, K., et al. Delivery of chemotherapeutic drugs in tumour cell-derived microparticles. Nat. Commun., 3, 2012 p. 1282.
93. [93] Harshyne, L.A., et al. Glioblastoma exosomes and IGF-1R/AS-ODN are immunogenic stimuli in a translational research immunotherapy paradigm. Cancer Immunol. Immunother. 64:3 (2015), 299–309.
94. [94] Andrews, D.W., et al. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J. Clin. Oncol. 19:8 (2001), 2189–2200.
95. [95] Zhuang, X., et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol. Ther. 19:10 (2011), 1769–1779.
96. [96] Bandyopadhyay, D., Farmer to pharmacist: curcumin as an anti-invasive and antimetastatic agent for the treatment of cancer. Front. Chem., 2, 2014, 113.
97. [97] Irving, G.R., et al. Prolonged biologically active colonic tissue levels of curcumin achieved after oral administration?a clinical pilot study including assessment of patient acceptability. Cancer Prev Res (Phila) 6:2 (2013), 119–128.
98. [98] Kooijmans, S.A., et al. Electroporation-induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles. J. Control. Release 172:1 (2013), 229–238.
99. [99] Hood, J.L., et al. Maximizing exosome colloidal stability following electroporation. Anal. Biochem. 448 (2014), 41–49.
100. [100] Batrakova, E.V., Kim, M.S., Using exosomes, naturally-equipped nanocarriers, for drug delivery. J. Control. Release 219 (2015), 396–405.
101. [101] Fuhrmann, G., et al. Cell-derived vesicles for drug therapy and diagnostics: opportunities and challenges. Nano Today 10:3 (2015), 397–409.
102. [102] Shen, B., et al. Protein targeting to exosomes/microvesicles by plasma membrane anchors. J. Biol. Chem. 286:16 (2011), 14383–14395.
103. [103] Villarroya-Beltri, C., et al. Analysis of microRNA and protein transfer by exosomes during an immune synapse. Methods Mol. Biol. 1024 (2013), 41–51.
104. [104] Koppers-Lalic, D., et al. Virus-modified exosomes for targeted RNA delivery; a new approach in nanomedicine. Adv. Drug Deliv. Rev. 65:3 (2013), 348–356.
105. [105] Mizutani, K., et al. Isolation of prostate cancer-related exosomes. Anticancer Res. 34:7 (2014), 3419–3423.
106. [106] Skog, J., et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 10:12 (2008), 1470–1476.
107. [107] Rabinowits, G., et al. Exosomal microRNA: a diagnostic marker for lung cancer. Clin. Lung Cancer 10:1 (2009), 42–46.
108. [108] Tavoosidana, G., et al. Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 108:21 (2011), 8809–8814.
109. [109] van der Meel, R., et al. Toward routine detection of extracellular vesicles in clinical samples. Int. J. Lab. Hematol. 36:3 (2014), 244–253.
110. [110] Witwer, K.W., et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J. Extracell Vesicles, 2, 2013.
111. [111] Van Deun, J., et al. The impact of disparate isolation methods for extracellular vesicles on downstream RNA profiling. J. Extracell Vesicles, 3, 2014.
112. [112] van der Pol, E., et al. Optical and non-optical methods for detection and characterization of microparticles and exosomes. J. Thromb. Haemost. 8:12 (2010), 2596–2607.
113. [113] Zarovni, N., et al. Integrated isolation and quantitative analysis of exosome shuttled proteins and nucleic acids using immunocapture approaches. Methods 87 (2015), 46–58.
114. [114] Kastelowitz, N., Yin, H., Exosomes and microvesicles: identification and targeting by particle size and lipid chemical probes. ChemBioChem 15:7 (2014), 923–928.
115. [115] Melo, S.A., et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523:7559 (2015), 177–182.
116. [116] Peinado, H., et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18:6 (2012), 883–891.
117. [117] Im, H., et al. Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor. Nat. Biotechnol. 32:5 (2014), 490–495.
118. [118] Taylor, D.D., Gercel-Taylor, C., MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 110:1 (2008), 13–21.
119. [119] Matsumura, T., et al. Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. Br. J. Cancer 113:2 (2015), 275–281.
120. [120] Sato-Kuwabara, Y., et al. The fusion of two worlds: non-coding RNAs and extracellular vesicles–diagnostic and therapeutic implications (Review). Int. J. Oncol. 46:1 (2015), 17–27.
121. [121] Pritchard, C.C., et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila) 5:3 (2012), 492–497.
122. [122] Gabriel, K., et al. Regulation of the tumor suppressor PTEN through exosomes: a diagnostic potential for prostate cancer. PLoS One, 8(7), 2013 p. e70047.
123. [123] Nilsson, J., et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br. J. Cancer 100:10 (2009), 1603–1607.
124. [124] Leucci, E., et al. Melanoma addiction to the long non-coding RNA SAMMSON. Nature 531:7595 (2016), 518–522.
125. [125] Fais, S., et al. Evidence-based clinical use of nanoscale extracellular vesicles in nanomedicine. ACS Nano 10:4 (2016), 3886–3899.
126. [126] Record, M., et al. Exosomes as intercellular signalosomes and pharmacological effectors. Biochem. Pharmacol. 81:10 (2011), 1171–1182.
127. [127] Sverdlov, E.D., Amedeo Avogadro's cry: what is 1 μg of exosomes?. Bioessays 34:10 (2012), 873–875.
128. [128] Laulagnier, K., et al. Characterization of exosome subpopulations from RBL-2H3 cells using fluorescent lipids. Blood Cells. Mol. Dis. 35:2 (2005), 116–121.
129. [129] Smith, Z.J., et al. Single exosome study reveals subpopulations distributed among cell lines with variability related to membrane content. J. Extracell Vesicles, 4, 2015, 28533.
130. [130] Chevillet, J.R., et al. Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proc. Natl. Acad. Sci. U. S. A. 111:41 (2014), 14888–14893.
131. [131] Jia, S., et al. Emerging technologies in extracellular vesicle-based molecular diagnostics. Expert Rev. Mol. Diagn. 14:3 (2014), 307–321.
132. [132] Street, J.M., Yuen, P.S., Star, R.A., Bioactive exosomes: possibilities for diagnosis and management of bladder cancer. J. Urol. 192:2 (2014), 297–298.
133. [133] Kalra, H., et al. Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma. Proteomics 13:22 (2013), 3354–3364.
134. [134] Shao, H., et al. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat. Med. 18:12 (2012), 1835–1840.
135. [135] Ueda, K., et al. Antibody-coupled monolithic silica microtips for highthroughput molecular profiling of circulating exosomes. Sci. Rep., 4, 2014, 6232.
136. [136] Rho, J., et al. Magnetic nanosensor for detection and profiling of erythrocyte-derived microvesicles. ACS Nano 7:12 (2013), 11227–11233.
137. [137] Zhao, Z., et al. A microfluidic ExoSearch chip for multiplexed exosome detection towards blood-based ovarian cancer diagnosis. Lab Chip 16:3 (2016), 489–496.
138. [138] Cretich, M., et al. Digital detection of biomarkers assisted by nanoparticles: application to diagnostics. Trends Biotechnol. 33:6 (2015), 343–351.
139. [139] Logozzi, M., et al. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One, 4(4), 2009 p. e5219.
140. [140] Hwang do, W., et al. Noninvasive imaging of radiolabeled exosome-mimetic nanovesicle using (99m)Tc-HMPAO. Sci. Rep., 5, 2015 p. 15636.
141. [141] Wiklander, O.P., et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J. Extracell Vesicles, 4, 2015, 26316.
142. [142] Smyth, T., et al. Biodistribution and delivery efficiency of unmodified tumor-derived exosomes. J. Control. Release 199 (2015), 145–155.
143. [143] Lee, S., et al. Activatable molecular probes for cancer imaging. Curr. Top. Med. Chem. 10:11 (2010), 1135–1144.
144. [144] Parolini, I., et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J. Biol. Chem. 284:49 (2009), 34211–34222.
145. [145] Chowdhury, R., et al. The use of molecular imaging combined with genomic techniques to understand the heterogeneity in cancer metastasis. Br. J. Radiol., 87(1038), 2014 p. 20140065.
146. [146] Sheridan, C., Exosome cancer diagnostic reaches market. Nat. Biotechnol. 34:4 (2016), 359–360.